- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05009043
COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt
COVID-19 Vaccine Hesitancy and Perceptions Among Teaching and Assisting Staff at Faculty of Dentistry, Ain Shams University in Egypt: A Cross-Sectional Study.
Study Overview
Status
Conditions
Detailed Description
To mitigate the rapid spread of COVID-19 and its massive impact on the economy worldwide, efforts have to be made to protect people against the disease, one of the most effective means was found to be vaccination. The range of technology in the development of COVID-19 vaccine is a striking feature where various approaches are being evaluated including, but not limited to: nucleic acid (DNA and RNA), recombinant protein, live-attenuated virus, inactivated virus and virus-like particles approaches. It is the responsibility of governments to ensure equity in the distribution and access to the novel vaccine. Authorized and currently available vaccines in Egypt include: 1) COVID-19 Vaccine AstraZeneca (AZD1222) which is an adenovirus vaccine manufactured in UK, 2) Sputnik V, a recombinant adenovirus vaccine manufactured in Russia and 3) BBIBP-CorV Sinopharm, which is an inactivated vaccine manufactured in China. The total number of vaccine doses administered in Egypt was reported to be 1,315 doses in March 2021.
However, vaccine availability is not enough to ensure large-scale immunization; success of vaccination programs depend greatly on the population's demand and acceptability of the vaccine. Governments should strive to understand determinants of vaccine acceptability and perception of people towards the vaccine. Although vaccination has largely contributed to decreasing the global burden of diseases and mortality, various factors can affect the acceptance of a new vaccine. "Vaccine hesitancy" has been declared by WHO as one of the ten global health threats worldwide, and has been defined as 'delay in acceptance or refusal of vaccination despite availability of vaccination services.' Causes of vaccine hesitancy include concerns about its safety, efficacy, personal beliefs, religious reasons, concerns about its rapid development as the rapid development of swine flu vaccine was previously associated with increased risk of Guillain-Barre syndrome, low benefits perceived and fear of side effects. Moreover, some people have concerns about the manufacturing process of the vaccine, as a defective polio vaccine lead to development of incident cases of polio and paralysis and death in earlier times.
In Egypt, healthcare workers are the first group to have access to COVID-19 vaccine and hence, act as a primary source of knowledge to the public about the vaccine, therefore it is crucial to estimate their level of perception and acceptability of the vaccine and determine factors affecting their acceptability. This will help inform stakeholders to make decisions regarding COVID-19 vaccination programs. To the best of our knowledge, this is the first study in Egypt targeting dental health professionals in particular, owing to their exclusive high exposure level to COVID-19 among healthcare workers
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 11311
- AIN shams university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Staff members at Faculty of Dentistry, Ain Shams University
- Egyptians.
Exclusion Criteria:
- Staff members who refuse to participate in the study.
- Staff members currently living abroad. (As their perception about COVID-19 situation and risk in Egypt will not be accurate)
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Staff members who accept/refuse vaccination against COVID-19
Time Frame: August 2021-October 2021
|
Percentage
|
August 2021-October 2021
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Perceived barriers and enablers of staff members to get vaccinated against COVID-19
Time Frame: August 2021-December 2021
|
August 2021-December 2021
|
|
|
Factors associated with acceptance of COVID-19 vaccination among staff members.
Time Frame: August 2021-December 2021
|
Demographics, previous COVID-19 experience, knowledge and attitude
|
August 2021-December 2021
|
|
Risk perception of COVID-19 among staff members.
Time Frame: August 2021-December 2021
|
August 2021-December 2021
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Amira Badran, PhD, AIN shams university
- Principal Investigator: Mariam Sharaf, Msc, AIN shams university
- Principal Investigator: Omar Taqa, Msc, AIN shams university
- Study Chair: Haneen Zahran, Msc, AIN shams university
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 960 (Other Identifier: Study Team)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitatsspital ZurichEnrolling by invitation
-
Alexandria UniversityCompleted